A new strategy for anticoagulation: The factor XI inhibitors

Area of Science:

• Pharmacology and Thrombosis Research
• Development of novel anticoagulant agents targeting specific coagulation factors.

Background:

• Direct oral anticoagulants (DOACs) are first-line treatments for atrial fibrillation and venous thromboembolism (VTE), offering improved efficacy and safety over vitamin K antagonists (VKAs).
• DOACs have limitations, including lack of benefit in specific patient populations (e.g., mechanical valves, antiphospholipid syndrome) and concerns regarding gastrointestinal bleeding.
• The development of factor XI and factor XII inhibitors is proposed to overcome DOAC limitations and expand anticoagulation's clinical utility.

Purpose of the Study:

• To provide an update on the rationale, pharmacological properties, and preliminary clinical findings of factor XI inhibitors.
• To explore the potential of factor XI inhibitors to decouple hemostasis from thrombosis, addressing the long-standing issue of bleeding as an unavoidable side effect of anticoagulation.

Main Methods:

• Review of emerging data on the role of factor XI in hemostasis and thrombosis.
• Analysis of the pharmacological profiles of developing factor XI inhibitors.
• Evaluation of preliminary clinical findings from studies investigating factor XI inhibitors.

Main Results:

• Factor XI plays a minor role in physiological hemostasis but a significant role in thrombosis development.
• Factor XI inhibitors aim to selectively inhibit thrombosis while preserving normal hemostasis, potentially reducing bleeding risk.
• Preliminary clinical data suggest potential efficacy and improved safety profiles for factor XI inhibitors.

Conclusions:

• Factor XI inhibitors represent a novel therapeutic strategy in anticoagulation, potentially offering a more favorable efficacy-safety balance.
• These agents challenge the dogma that bleeding is an unavoidable consequence of anticoagulant therapy.
• Further research and clinical trials are warranted to fully establish the role of factor XI inhibitors in various clinical settings.